Overview
Oma Fertility runs a network of fertility clinics that use artificial intelligence and robotics together with a human-centered approach to deliver IVF, IUI, and egg freezing. They own the clinics to directly manage the patient experience and costs, and they price treatments at lower, ethical rates to make care more affordable. A core offering is Oma Sperm InSight, an FDA-registered AI tool that helps embryologists choose the best sperm by analyzing many more cells than manual methods, with intracytoplasmic sperm injection (ICSI) included as a standard part of packages. Their differentiators are vertical integration, AI-assisted sperm selection, and a focus on lowering costs while improving embryo selection, aiming to increase IVF success rates and reduce the financial and emotional burden on patients.
Work here?Claim your company
Simplify's take
What believers are saying
- 2023 expansion into Atlanta, New York, and St. Louis showed demand validation.
- Pinnacle's network likely preserved patient flow into Oma-branded lab capabilities.
- Oma's low-cost positioning still matches affordability pressure in cash-pay fertility markets.
What critics are saying
- August 2023 clinics joined Pinnacle Fertility, erasing Oma's standalone distribution.
- 2025 reports said Thread Robotics faced closure and clinic sales discussions.
- Laid-off corporate staff in August 2025 signal operational contraction before a 2026 shutdown.
What makes Oma Fertility unique
- Oma Sperm InSight targets sperm selection, a bottleneck in IVF labs.
- 2023 clinics combined AI, robotics, and human-centered care across multiple cities.
- Ethical pricing and standard ICSI reduced sticker shock versus traditional IVF bundles.
Help us improve and share your feedback! Did you find this helpful?